217 related articles for article (PubMed ID: 32027754)
41. NKG2D ligands expression and NKG2D-mediated NK activity in Sezary patients.
Dulphy N; Berrou J; Campillo JA; Bagot M; Bensussan A; Toubert A
J Invest Dermatol; 2009 Feb; 129(2):359-64. PubMed ID: 18754036
[TBL] [Abstract][Full Text] [Related]
42. Celiac Disease-Related Inflammation Is Marked by Reduction of Nkp44/Nkp46-Double Positive Natural Killer Cells.
Marafini I; Monteleone I; Di Fusco D; Sedda S; Cupi ML; Fina D; Paoluzi AO; Pallone F; Monteleone G
PLoS One; 2016; 11(5):e0155103. PubMed ID: 27171408
[TBL] [Abstract][Full Text] [Related]
43. Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3.
Yang CM; Yoon JC; Park JH; Lee JM
PLoS One; 2017; 12(4):e0175793. PubMed ID: 28410411
[TBL] [Abstract][Full Text] [Related]
44. Activation Receptor-Dependent IFN-γ Production by NK Cells Is Controlled by Transcription, Translation, and the Proteasome.
Piersma SJ; Pak-Wittel MA; Lin A; Plougastel-Douglas B; Yokoyama WM
J Immunol; 2019 Oct; 203(7):1981-1988. PubMed ID: 31444264
[TBL] [Abstract][Full Text] [Related]
45. Recognition of viral hemagglutinins by NKp44 but not by NKp30.
Arnon TI; Lev M; Katz G; Chernobrov Y; Porgador A; Mandelboim O
Eur J Immunol; 2001 Sep; 31(9):2680-9. PubMed ID: 11536166
[TBL] [Abstract][Full Text] [Related]
46. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias.
Nowbakht P; Ionescu MC; Rohner A; Kalberer CP; Rossy E; Mori L; Cosman D; De Libero G; Wodnar-Filipowicz A
Blood; 2005 May; 105(9):3615-22. PubMed ID: 15657183
[TBL] [Abstract][Full Text] [Related]
47. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
[TBL] [Abstract][Full Text] [Related]
48. Aberrant natural killer (NK) cell activation and dysfunction among ART-treated HIV-infected adults in an African cohort.
Nabatanzi R; Bayigga L; Cose S; Rowland-Jones S; Canderan G; Joloba M; Nakanjako D
Clin Immunol; 2019 Apr; 201():55-60. PubMed ID: 30817998
[TBL] [Abstract][Full Text] [Related]
49. Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells.
Capuano C; Romanelli M; Pighi C; Cimino G; Rago A; Molfetta R; Paolini R; Santoni A; Galandrini R
Cancer Res; 2015 Oct; 75(19):4097-108. PubMed ID: 26229120
[TBL] [Abstract][Full Text] [Related]
50. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
Kellner C; Maurer T; Hallack D; Repp R; van de Winkel JG; Parren PW; Valerius T; Humpe A; Gramatzki M; Peipp M
J Immunol; 2012 Nov; 189(10):5037-46. PubMed ID: 23066150
[TBL] [Abstract][Full Text] [Related]
51. Retroviral gene transfer into primary human NK cells activated by IL-2 and K562 feeder cells expressing membrane-bound IL-21.
Streltsova MA; Barsov E; Erokhina SA; Kovalenko EI
J Immunol Methods; 2017 Nov; 450():90-94. PubMed ID: 28802832
[TBL] [Abstract][Full Text] [Related]
52. Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin.
Jarahian M; Fiedler M; Cohnen A; Djandji D; Hämmerling GJ; Gati C; Cerwenka A; Turner PC; Moyer RW; Watzl C; Hengel H; Momburg F
PLoS Pathog; 2011 Aug; 7(8):e1002195. PubMed ID: 21901096
[TBL] [Abstract][Full Text] [Related]
53. Comparison of Phenotypic and Functional Characteristics Between Canine Non-B, Non-T Natural Killer Lymphocytes and CD3
Lee SH; Shin DJ; Kim Y; Kim CJ; Lee JJ; Yoon MS; Uong TNT; Yu D; Jung JY; Cho D; Jung BG; Kim SK; Suh GH
Front Immunol; 2018; 9():841. PubMed ID: 29755462
[TBL] [Abstract][Full Text] [Related]
54. NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation.
Vacca P; Martini S; Garelli V; Passalacqua G; Moretta L; Mingari MC
Eur J Immunol; 2013 Feb; 43(2):550-61. PubMed ID: 23192659
[TBL] [Abstract][Full Text] [Related]
55. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
56. Selective role of mevalonate pathway in regulating perforin but not FasL and TNFalpha release in human Natural Killer cells.
Poggi A; Boero S; Musso A; Zocchi MR
PLoS One; 2013; 8(5):e62932. PubMed ID: 23667543
[TBL] [Abstract][Full Text] [Related]
57. Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas.
Hagelstein I; Lutz MS; Schmidt M; Heitmann JS; Malenke E; Zhou Y; Clar KL; Kopp HG; Jung G; Salih HR; Märklin M; Hinterleitner C
Front Immunol; 2021; 12():653081. PubMed ID: 33936075
[TBL] [Abstract][Full Text] [Related]
58. Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation.
Marras F; Nicco E; Bozzano F; Di Biagio A; Dentone C; Pontali E; Boni S; Setti M; Orofino G; Mantia E; Bartolacci V; Bisio F; Riva A; Biassoni R; Moretta L; De Maria A
Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11970-5. PubMed ID: 23818644
[TBL] [Abstract][Full Text] [Related]
59. Up-regulation of NKG2A inhibitory receptor on circulating NK cells contributes to transfusion-induced immunodepression in patients with β-thalassemia major.
Zou Y; Song ZX; Lu Y; Liang XL; Yuan Q; Liao SH; Bao JJ
J Huazhong Univ Sci Technolog Med Sci; 2016 Aug; 36(4):509-513. PubMed ID: 27465324
[TBL] [Abstract][Full Text] [Related]
60. Human NK cytotoxicity against porcine cells is triggered by NKp44 and NKG2D.
Forte P; Lilienfeld BG; Baumann BC; Seebach JD
J Immunol; 2005 Oct; 175(8):5463-70. PubMed ID: 16210654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
